References
1. Santiago Borrero PJ, Rodríguez-Pérez Y, Renta JY, Izquierdo NJ, del
Fierro L, Muñoz D, et al. Genetic Testing for Oculocutaneous Albinism
Type 1 and 2 and Hermansky–Pudlak Syndrome Type 1 and 3 Mutations in
Puerto Rico. Journal of Investigative Dermatology. 2006
Jan;126(1):85–90.
2. Nazir HF, AL Sukaiti N, Khater D, Elbeshlawy I, Hassanein N.
Hermansky-Pudlak Syndrome: Spectrum in Oman. J Pediatr Hematol Oncol.
2023 Apr;45(3):e389–94.
3. Introne WJ, Huizing M, Malicdan MC V, O’Brien KJ, Gahl WA.
Hermansky-Pudlak Syndrome. GeneReviews .
4. Bagheri A, Abdollahi A. Hermansky-pudlak syndrome; a case report. J
Ophthalmic Vis Res. 2010 Oct;5(4):269–72.
5. Harmon KR, Witkop CJ, White JG, King RA, Peterson M, Moore D, et al.
Pathogenesis of pulmonary fibrosis: platelet-derived growth factor
precedes structural alterations in the Hermansky-Pudlak syndrome. J Lab
Clin Med. 1994 Apr;123(4):617–27.
6. Garay SM, Gardella JE, Fazzini EP, Goldring RM. Hermansky-Pudlak
syndrome. Pulmonary manifestations of a ceroid storage disorder. Am J
Med. 1979 May;66(5):737–47.
7. Schinella RA, Greco MA, Cobert BL, Denmark LW, Cox RP.
Hermansky-Pudlak syndrome with granulomatous colitis. Ann Intern Med.
1980 Jan;92(1):20–3.
8. Summers CG, Hand JL. Hermansky-Pudlak syndrome. Post TedW, editor.
UpToDate, Waltham, MA;
9. Pierson DM, Ionescu D, Qing G, Yonan AM, Parkinson K, Colby TC, et
al. Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Respiration.
2006;73(3):382–95.
10. Lorenzi L, Tabellini G, Vermi W, Moratto D, Porta F, Notarangelo LD,
et al. Occurrence of Nodular Lymphocyte-Predominant Hodgkin Lymphoma in
Hermansky-Pudlak Type 2 Syndrome Is Associated to Natural Killer and
Natural Killer T Cell Defects. PLoS One. 2013 Nov 26;8(11):e80131.
11. Cavounidis A, Pandey S, Capitani M, Friedrich M, Cross A, Gartner L,
et al. Hermansky-Pudlak syndrome type 1 causes impaired anti-microbial
immunity and inflammation due to dysregulated immunometabolism. Mucosal
Immunol. 2022 Nov;15(6):1431–46.
12. Berliner N, Horwitz M, Loughran TP. Congenital and Acquired
Neutropenia. Hematology. 2004 Jan 1;2004(1):63–79.
13. Lalvani A, Millington KA. T Cells and Tuberculosis: Beyond
Interferon‐γ. J Infect Dis. 2008 Apr;197(7):941–3.
14. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An
essential role for interferon gamma in resistance to Mycobacterium
tuberculosis infection. Journal of Experimental Medicine. 1993 Dec
1;178(6):2249–54.
15. Ottenhoff THM, Kumararatne D, Casanova JL. Novel human
immunodeficiencies reveal the essential role of type-1 cytokines in
immunity to intracellular bacteria. Immunol Today. 1998
Nov;19(11):491–4.
16. Prandini A, Salvi V, Colombo F, Moratto D, Lorenzi L, Vermi W, et
al. Impairment of dendritic cell functions in patients with adaptor
protein-3 complex deficiency. Blood. 2016 Jun 30;127(26):3382–6.
17. Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM,
et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak
syndrome type II. Blood. 2006 Jul 1;108(1):81–7.
18. Lucchini G, Marsh R, Gilmour K, Worth A, Nademi Z, Rao A, et al.
Treatment dilemmas in asymptomatic children with primary hemophagocytic
lymphohistiocytosis. Blood. 2018 Nov 8;132(19):2088–96.
19. Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H,
et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis:
long-term results of the HLH-94 treatment protocol. Blood. 2011 Oct
27;118(17):4577–84.
20. Dell’Acqua F, Saettini F, Castelli I, Badolato R, Notarangelo LD,
Rizzari C. Hermansky-Pudlak syndrome type II and lethal hemophagocytic
lymphohistiocytosis: Case description and review of the literature. J
Allergy Clin Immunol Pract. 2019 Sep;7(7):2476-2478.e5.